RxDoctor Payments Data

Scott Smith, MD

Family Medicine · Pleasant Grove, UTNPI 1336257617

Payments from drug & device makers

$6,064in general payments, 2019–2025

Across 382 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi-aventis U.S. LLC$406
  • Lilly USA, LLC$404
  • AstraZeneca$371
  • Bayer$292
  • Johnson & Johnson$241
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$6,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,064 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$126,095
Medicare patients
247
Services billed
4,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$133,134
JardianceEmpagliflozin83$103,287
EliquisApixaban116$99,518
TrulicityDulaglutide52$56,170
XareltoRivaroxaban45$48,187
OzempicSemaglutide21$30,940
FarxigaDapagliflozin Propanediol26$26,900
MyrbetriqMirabegron29$23,499
Xtampza ErOxycodone Myristate28$18,449
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$16,929
GlyxambiEmpagliflozin/Linagliptin11$15,377
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$14,493
GemtesaVibegron14$13,934
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,650
Fiasp FlextouchInsulin Aspart (Niacinamide)15$8,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$404$189,305148 claims
Boehringer IngelheimJardiance, Glyxambi$223$118,66594 claims
PfizerEliquis$151$99,518116 claims
Johnson & JohnsonXarelto$241$48,18745 claims
Novo NordiskOzempic$212$30,94021 claims
AstraZenecaFarxiga$371$26,90026 claims
Astellas Pharma US IncMyrbetriq$223$23,49929 claims
Collegium Pharmaceutical, Inc.Xtampza Er$38$18,44928 claims
Sumitomo Pharma America, Inc.Gemtesa$41$13,93414 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$406$11,65013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Pleasant Grove

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →